-
Product Insights
Arsenal Solar PV Park
Arsenal Solar PV Park is a solar PV project located in Pamplemousses, Mauritius. The project is owned and being developed by Central Electricity Board; GreenYellow SAS. The project is at the permitting stage. Empower your strategies with our Arsenal Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Arsenic Trioxide in Mantle Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Arsenic Trioxide in Mantle Cell Lymphoma Drug Details: Arsenic trioxide is under development for the...
-
Product Insights
Redstone Arsenal Solar PV Park
Redstone Arsenal Solar PV Park is a solar PV project located in Alabama, United States. The project is owned by TotalEnergies Renewables USA LLC and was developed by SunPower Corp. The project came online in 2018. Empower your strategies with our Redstone Arsenal Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Arsenic Trioxide in Acute Promyelocytic Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Arsenic Trioxide in Acute Promyelocytic Leukemia Drug Details: Arsenic trioxide is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Arsenic Trioxide in Myelodysplastic Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Arsenic Trioxide in Myelodysplastic Syndrome Drug Details:Arsenic trioxide is under development for the treatment of relapsed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Arsenic Trioxide in Myeloproliferative Disorders
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Arsenic Trioxide in Myeloproliferative Disorders Drug Details:Arsenic trioxide is under development for the treatment of relapsed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Arsenic Trioxide in Chronic Myelomonocytic Leukemia (CMML)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Arsenic Trioxide in Chronic Myelomonocytic Leukemia (CMML) Drug Details:Arsenic trioxide is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Arsenic Trioxide 1 in Graft Versus Host Disease (GVHD)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Arsenic Trioxide 1 in Graft Versus Host Disease (GVHD) Drug Details: Arsenic trioxide is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PAX-1 in Metastatic Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PAX-1 in Metastatic Breast Cancer Drug Details: PAX-1 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PAX-1 in Non-Small Cell Lung Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PAX-1 in Non-Small Cell Lung Carcinoma Drug Details: PAX-1 is under development for the treatment...